drugset / Trial / NCT00262054

Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)

NCT00262054

Phase 4 Completed 4570 enrolled German Heart Center Munich
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether bivalirudin given during PCI is associated with better outcomes compared to un-fractionated heparin.

Timeline

Start
2005-11
Primary completion
2008-02
Completion
2008-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalirudin Peptide 1.75 mg/kg Intravenous
Comparator Heparin Other / unclassified 140 iu/kg Intravenous